Abbott Laboratories (NYSE:ABT) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies ...

Abbott Laboratories is under fresh scrutiny as price targets are reset, with some analysts trimming their expectations and ...

Abbott Labs Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding value.

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Abbott's dividend track record demonstrates consistency. The company has increased its dividend for 13 consecutive years, with the annual payout growing from $1.04 in 2016 to $2.36 in 2025 - a 127% ...

A Missouri appellate court has upheld a $495 million verdict against Abbott Laboratories in a case over whether its formula ...

CNBC's Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that's been weighed down by ongoing litigation for several months but just won a major lawsuits it faces.

Abbott Laboratories’ stock took a direct hit, wiping out nearly 10% of its market value following its Q4 earnings. Response? The CEO bought $2 million shares. Robert B. Ford, CEO of Abbott ...

In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the ...

Abbott Laboratories (ABT) stock has been punished hard in 2026, and the question is whether that punishment has overshot the fundamentals. Abbott Labs is a quality franchise at a discounted price, but ...

Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues. The medical device leader boasts a strong ...

This company has delivered earnings and dividend growth over time. Abbott’s innovation and a new acquisition could spur more growth in the years to come. 10 stocks we like better than Abbott ...